参考文献/References:
[1] GROSS G,WAKS T,ESHHAR Z.Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J].Proc Natl Acad Sci USA,1989,86(24):10024-10028.
[2] PORTER D L,LEVINE B L,KALOS M,et al.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J].N Engl J Med,2011,365(8):725-733.
[3] LEYFMAN Y.Chimeric antigen receptors:unleashing a new stage of anti-cancer therapy[J].Cancer Cell Int,2018,18:182.
[4] SCHMIDTS A,MAUS M V.Making CAR T cells a solid option for solid tumors[J].Front Immunol,2018,9:2593.
[5] AVANZI M P,YEKU O,LI X,et al.Engineered tumor-targeted T cells mediated enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system[J].Cell Rep,2018,23(7):2130-2141.
[6] ZHANG C,WANG Z,YANG Z,et al.Phase I escalating-dose trial of CAR-T therapy targeting CEA+metastatic colorectal cancers[J].Mol Ther,2017,25(5):1248-1258.
[7] MOUNT C W,MAJZNER R G,SUNDARESH S,et al.Potent antitumor efficacy of anti-GD2 CAR-T cells in H3-K27M+diffuse midline gliomas[J].Nat Med,2018,24(5):572-579.
[8] LOUIS C U,SAVOLDO B,DOTTI G,et al.Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma[J].Blood,2011,118(23):6050-6056.
[9] AHMED N,BRAWLEY V S,HEGDE M,et al.Human epidermal growth factor receptor 2(HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma[J].J Clin Oncol,2015,33(15):1688-1696.
[10] BROWN C E,ALIZADEH D,STARR R,et al.Regression of glioblastoma after chimeric antigen receptor T-cell therapy[J].N Engl J Med,2016,375(26):2561-2569.
[11] BEATTY G L,O′HARA M H,LACEY S F,et al.Activity of mesothelin-specific chimeric antigen receptor T cells against pancreatic carcinoma metastases in phase 1 trial[J].Gastroenterology,2018,55(1):29-32.
[12] HE J,ZHANG Z,LV S,et al.Engineered CAR T cells targeting mesothelin by piggyBac transposon system for the treatment of pancreatic cancer[J].Cell Immunol,2018,329:31-40.
[13] PARK Y P,JIN L,BENNETT K B,et al.CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma[J].Oral Oncol,2018,78:145-150.
[14] JIN L,GE H,LONG Y,et al.CD70,a novel target of CAR-T cell therapy for gliomas[J].Neuro Oncol,2018,20(1):55-65.
[15] LI H,HUANG Y,JIANG D Q,et al.Antitumor activity of EGFR-specific CAR T cells against non-small-cell lung cancer cells in vitro and in mice[J].Cell Death Dis,2018,9(2):177.
[16] JIANG H,GAO H,KONG J,et al.Selective targeting of glioblastoma with EGFRvIII/EGFR bitargeted chimeric antigen receptor T cell[J].Cancer Immunol Res,2018,6(11):1314-1326.
[17] PAN Z,DI S,SHI B,et al.Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein[J].Cancer Immunol Immunother,2018,67(10):1621-1634.
[18] KARACHALIOU N,LAZZARI C,VERLICCHI A,et al.Her3 as a therapeutic target in cancer[J].Bio Drugs,2017,31(1):63-73.
[19] KAWAKAMI H,YONESAKA K.Her3 and its ligand,heregulin,as targets for cancer therapy[J].Recent Pat Anticancer Drug Discov,2016,11(3):267-274.
[20] BASELGA J,SWAIN S M.Novel anticancer targets:revisiting ERBB2 and discovering ERBB3[J].Nat Rev Cancer,2009,9(7):463-475.
[21] MOTA J M,COLLIER K A,BARROS COSTA R L,et al.A comprehensive review of heregulins,HER3,and HER4 as potential therapeutic targets in cancer[J].Oncotarget,2017,8(51):89284-89306.
[22] KOL A,TERWISSCHA VAN SCHELTINGA A G,TIMMER-BOSSCHA H,et al.Her3,serious partner in crime:therapeutic approaches and potential biomarkers for effect of Her3-targeting[J].Pharmacol Ther,2014,143(1):1-11.
[23] ARTEAGA C L,ENGELMAN J A.ERBB receptors:from oncogene discovery to basic science to mechanism-based cancer therapeutics[J].Cancer Cell,2014,25(3):282-303.
[24] MA J,LYU H,HUANG J,et al.Targeting of erbB3 receptors to overcome resistance in cancer treatment[J].Mol Cancer,2014,13:105.
[25] ZUO B L,YAN B,ZHENG G X,et al.Targeting and suppression of HER3-positive breast cancer by T lymphocytes expressing a heregulin chimeric antigen receptor[J].Cancer Immunol Immunother,2018,67(3):393-401.
[26] JOYCE J A,FEARON D T.T cell exclusion,immune privilege,and the tumor microenvironment[J].Science,2015,348(6230):74-80.
[27] ZHANG E,GU J,XU H.Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors[J].Mol Cancer,2018,17(1):7.
[28] ABIKO K,MATSUMURA N,HAMANISHI J,et al.IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer[J].Br J Cancer,2015,112(9):1501-1509.
[29] FOSTER A E,DOTTI G,LU A,et al.Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-β receptor[J].J Immunother,2008,31(5):500-505.
[30] LONG A H,HASO W M,SHERN J F,et al.4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors[J].Nat Med,2015,21(6):581-590.
[31] PEGRAM H J,LEE J C,HAYMAN E G,et al.Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning[J].Blood,2012,119(8):4133-4141.
[32] ZHANG T,SENTMAN C L.Cancer immunotherapy using a bispecific NK receptor fusion protein that engages both T cells and tumor cells[J].Cancer Res,2011,71(6):2066-2076.
[33] BURGA R A,THORN M,POINT G R,et al.Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T[J].Cancer Immunol Immunother,2015,64(7):817-829.
[34] PROSSER M E,BROWN C E,SHAMI A F,et al.Tumor PD-L1 co-stimulates primary human CD8+ cytotoxic T cells modified to express a PD1:CD28 chimeric receptor[J]. Mol Immunol,2012,51(3/4):263-272.
[35] LEEN A M,SUKUMARAN S,WATANABE N,et al.Reversal of tumor immune inhibition using a chimeric cytokine receptor[J].Mol Ther,2014,22(6):1211-1220.
[36] JOHN L B,KERSHAW M H,DARCY P K.Blockade of PD-1 immunosuppression boosts CAR T-cell therapy[J].Oncoimmunology,2013,2(10):e26286.
[37] MORGAN R A,YANG J C,KITANO M,et al.Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2[J].Mol Ther,2010,18(4):843-851.
[38] SHIMABUKURO-VORNHAGEN A,GDEL P,SUBKLEWE M,et al.Cytokine release syndrome[J].J Immunother Cancer,2018,6(1):56.
[39] HUNTER C A,JONES S A.IL-6 as a keystone cytokine in health and disease[J].Nat Immunol,2015,16(5):448-457.
[40] HAY K A,HANAFI L A,LI D,et al.Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T cell therapy[J].Blood,2017,130(21):2295-2306.
[41] OBSTFELD A E,FREY N V,MANSFIELD K,et al.Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy:clinicopathological insights[J].Blood,2017,130(23):2569-2572.
[42] ALDERTON G K.Immunotherapy:engineered T cells for all[J].Nat Rev Cancer,2017,17(4):206-207.
[43] QASIM W,ZHANG H,SAMARASINHE S,et al.Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR-T cells[J].Sci Transl Med,2017,9(374):pii:eaaj2013.DOI:10.1126/scitranslmed.aaj2013.
[44] REN J,LIU X,FANG C,et al.Multiplex genome editing to generate universal CAR-T cells resistant to PD1 inhibition[J].Clin Cancer Res,2017,23(9):2255-2266.